Compare Aptiv PLC (APTV) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aptiv PLC vs Sanofi SA — how do they compare? Aptiv PLC trades at $50 (market cap $10.34B), while Sanofi SA trades at $43.52 (market cap $104.57B). The key difference: Sanofi SA is far larger — about 10.1× Aptiv PLC's market cap, and Sanofi SA pays a 5.56% dividend while Aptiv PLC pays none. Which is the better fit depends on your goals.
| APTV | SNY | |
|---|---|---|
Market Cap | $10.34B | $104.57B |
Sector | Consumer Cyclical | Health |
52-Week High | $76.82 | $52.34 |
52-Week Low | $46.30 | $41.33 |
Enterprise Value | $15.27B | $124.48B |
Dividend Yield | — | 5.56% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
